Aktien Sensor

Fresenius Medical Care AG has announced a share buy-back program aimed at returning value to its shareholders, which is expected to boost earnings per share and potentially increase the stock’s value, amidst a cautiously optimistic European market e…

West Pharmaceutical Services, a key player in the drug delivery and packaging industry, faces a leadership void after Senior Vice President Kimberly Banks MacKay’s departure, potentially threatening the company’s strategic coherence and operational …

EssilorLuxottica’s share price has declined modestly following the passing of Giorgio Armani, but the company’s management is expected to weigh potential partnership or competitive responses to LVMH’s plans to deepen Armani’s global footprint.

Elevance Health has announced a strategic refocus, reaffirming its 2025 earnings guidance and exiting standalone Medicare Part D plans, positioning the company for greater profitability and investor confidence in the health-insurance sector.

Centene Corporation’s stock has surged in recent trading sessions, driven by the company’s reaffirmation of its 2025 earnings outlook and steady performance in Medicare ratings, despite concerns over the expiration of enhanced subsidies under the Af…

AbbVie’s stock price reached a record high after the company’s drug Rinvoq had its exclusivity extended to 2037, boosting the company’s long-term growth outlook.

Merck KGaA’s recent 2.56% share price decline is a symptom of broader market corrections, but the company’s diversified pipeline, strategic positioning in high-growth markets, and disciplined capital management position it well for long-term growth …

Astellas Pharma Inc. is navigating a complex market landscape, with opportunities for growth in China’s evolving intellectual property landscape and the emerging TROP2-targeted antibody-drug conjugate market, but faces challenges in innovation, geog…

Quest Diagnostics Inc. is navigating the complexities of healthcare regulation through proactive engagement with PAMA reform, positioning itself for stable and potentially higher revenue streams in the medium term.

Straumann Holding AG’s share price has declined by 15.88% over the past three years, but the company’s solid fundamentals and strategic positioning suggest it remains a compelling investment opportunity in the dental implant sector.